Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00828607

Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses

Liver Tumors Clinical Trial

Official title:
Characterization of Liver Masses With Contrast Enhanced Ultrasound (CEUS): A Comparison With Standard Institutional Contrast Enhanced CT (CECT) or MR Scan (CEMRI)

Clinical Trial Summary

This comparison study is performed to show equivalence of CEUS with CECT or CEMR to diagnose noninvasively focal liver masses. This is a multi-center prospective cohort study of 250 subjects, which will be performed at four institutions in Canada. Subjects with a focal liver mass, measuring at least 2.5 centimeters in maximal diameter, will undergo a conventional baseline sonogram followed by a contrast enhanced ultrasound (CEUS). CEUS will be performed on standard ultrasound scanners with contrast specific imaging capability. The contrast agent used is Definity (Lantheus Medical Imaging, Billerica,MA) All subjects will have either a dedicated hepatic contrast enhanced CT or MR scan within 60 days of the CEUS as per the standard of care in the institution. Anonymized image files from all imaging will be shown independently to two readers, blinded to all clinical and demographic data, who will predict malignancy and diagnosis.

Clinical Trial Description

This comparison study is performed to show equivalence of CEUS with CECT or CEMR to diagnose noninvasively focal liver masses. This is a multi-center prospective cohort study of 250 subjects, which will be performed at four institutions in Canada. Subjects with a focal liver mass, measuring at least 2.5 centimeters in maximal diameter, will undergo a conventional baseline sonogram followed by a contrast enhanced ultrasound (CEUS). CEUS will be performed on standard ultrasound scanners with contrast specific imaging capability. The contrast agent used is Definity (Lantheus Medical Imaging, Billerica,MA) All subjects will have either a dedicated hepatic contrast enhanced CT or MR scan within 60 days of the CEUS as per the standard of care in the institution. Anonymized image files from all imaging will be shown independently to two readers, blinded to all clinical and demographic data, who will predict malignancy and diagnosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00828607
Study type Observational
Source Foothills Medical Centre
Contact
Status Completed
Phase N/A
Start date January 2009
Completion date December 2016
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01197820 - Hepatic and Renal Thermography Using Magnetic Resonance Imaging N/A
Terminated NCT00942383 - Freehand Ultrasound Elasticity Imaging in Liver Surgery
Completed NCT01782573 - The Efficacy of Chlorhexidine Gluconate Pre - Disinfection Scrubbing in Preventing Surgical Site Infections for Hepatectomy Patients Phase 4
Active, not recruiting NCT03432806 - A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
Completed NCT01403727 - Electromagnetic Tracking of Devices During Biopsy Procedures N/A
Recruiting NCT00691691 - Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors Phase 2
Terminated NCT00955097 - Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors Phase 1
Recruiting NCT02184182 - Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS) Phase 2
Completed NCT02162732 - Molecular-Guided Therapy for Childhood Cancer N/A
Recruiting NCT05990257 - CMRA for US-guided-MWA of Liver Tumors N/A
Completed NCT00960609 - Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study N/A
Completed NCT05445973 - Added Value of Contrast-enhanced Ultrasonography for Percutaneous Radiofrequency Ablation N/A
Completed NCT03171428 - Hepatectomy With or Without the Thoraco-abdominal Approach N/A
Completed NCT02509507 - Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Phase 1/Phase 2
Completed NCT00877136 - A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Terminated NCT04315883 - Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors
Completed NCT01031784 - Radioactive Holmium Microspheres for the Treatment of Liver Metastases Phase 1
Active, not recruiting NCT00845689 - Prevention of Liver Damage During Liver Surgery Phase 1/Phase 2